Hypothesis: A single clinical trial plus causal evidence of effectiveness is sufficient for drug approval

被引:46
作者
Peck, CC
Rubin, DB
Sheiner, LB
机构
[1] Univ Calif San Francisco, Sch Med, Dept Lab Med, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Sch Med, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Sch Pharm, Dept Lab Med, San Francisco, CA 94143 USA
[4] Georgetown Univ, Sch Med, Ctr Drug Dev Sci, Off Associate Dean Clin Res, Washington, DC USA
[5] Harvard Univ, Dept Stat, Cambridge, MA 02138 USA
[6] Univ Calif San Francisco, Sch Pharm, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA
关键词
D O I
10.1016/S0009-9236(03)00018-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
引用
收藏
页码:481 / 490
页数:10
相关论文
共 18 条
[1]   Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].
Atkinson, AJ ;
Colburn, WA ;
DeGruttola, VG ;
DeMets, DL ;
Downing, GJ ;
Hoth, DF ;
Oates, JA ;
Peck, CC ;
Schooley, RT ;
Spilker, BA ;
Woodcock, J ;
Zeger, SL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95
[2]   Criteria for the validation of surrogate endpoints in randomized experiments [J].
Buyse, M ;
Molenberghs, G .
BIOMETRICS, 1998, 54 (03) :1014-1029
[3]  
FDA, 1998, GUID IND PROV CLIN E
[4]  
*FDA TASK FORC RIS, 1999, MAN RISKS MED PROD U
[5]  
Fisher LD, 1999, DRUG INF J, V33, P265, DOI 10.1177/009286159903300130
[6]   Principal stratification in causal inference [J].
Frangakis, CE ;
Rubin, DB .
BIOMETRICS, 2002, 58 (01) :21-29
[7]   Simulation of clinical trials [J].
Holford, NHG ;
Kimko, HC ;
Monteleone, JPR ;
Peck, CC .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2000, 40 :209-234
[8]  
PECK CC, 1996, SEN LAB HUM RES COMM
[9]  
PECK CC, 2002, DRUG INF J, V36, P517
[10]   THE RANDOMIZED CONCENTRATION-CONTROLLED TRIAL - AN EVALUATION OF ITS SAMPLE-SIZE EFFICIENCY [J].
SANATHANAN, LP ;
PECK, CC .
CONTROLLED CLINICAL TRIALS, 1991, 12 (06) :780-794